TSHA
Company Description
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 9.77M | 8.33M | 15.45M | 2.50M | 0 | 0 | 0 |
| Net Income | (109.00M) | (89.30M) | (111.57M) | (166.01M) | (174.52M) | (43.00M) | (1.11M) |
| EPS | -0.34 | -0.36 | -0.96 | -3.78 | -4.64 | -3.40 | -0.03 |
| Free Cash Flow | (93.83M) | (81.60M) | (80.39M) | (113.26M) | (138.60M) | (39.81M) | 135,000 |
| FCF / Share | -0.29 | -0.33 | -0.69 | -2.58 | -3.68 | -2.25 | 0.00 |
| Operating CF | (93.09M) | (81.22M) | (73.02M) | (88.39M) | (117.04M) | (30.73M) | 135,000 |
| Total Assets | 343.32M | 160.36M | 172.73M | 126.28M | 213.96M | 258.88M | 15,000 |
| Total Debt | 18.17M | 63.18M | 61.11M | 59.93M | 63.09M | 0 | 0 |
| Cash & Equiv | 319.77M | 139.04M | 143.94M | 87.88M | 149.10M | 251.25M | 0 |
| Book Value | 246.94M | 71.53M | 74.94M | 949,000 | 95.38M | 251.30M | (135,000) |
| Return on Equity | -0.44 | -1.25 | -1.49 | -174.94 | -1.83 | -0.17 | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 5.49M | 0 | 1.99M | 2.30M | 2.02M | 1.79M | 1.11M | 3.41M | 3.60M | 4.75M |
| Net Income | (46.64M) | (42.41M) | (27.85M) | (32.73M) | (26.88M) | (21.53M) | (18.79M) | (25.52M) | (20.93M) | (24.06M) | 47.74M | (117.09M) |
| EPS | -0.13 | -0.12 | -0.08 | -0.09 | -0.09 | -0.08 | -0.09 | -0.10 | -0.09 | -0.10 | 0.26 | -0.93 |
| Free Cash Flow | (40.42M) | (43.90M) | (26.97M) | (24.27M) | (20.18M) | (22.40M) | (18.31M) | (21.65M) | (21.70M) | (19.94M) | (16.13M) | (21.45M) |
| FCF / Share | -0.11 | -0.12 | -0.08 | -0.07 | -0.07 | -0.08 | -0.09 | -0.08 | -0.09 | -0.09 | -0.09 | -0.17 |
| Operating CF | (40.42M) | (40.88M) | (26.72M) | (24.17M) | (20.18M) | (22.02M) | (18.31M) | (21.61M) | (21.50M) | (19.80M) | (16.12M) | (17.95M) |
| Total Assets | 470.43M | 300.35M | 343.32M | 316.55M | 333.33M | 138.36M | 160.36M | 180.22M | 200.39M | 153.00M | 172.73M | 195.77M |
| Total Debt | 55.55M | 17.77M | 18.17M | 69.08M | 59.60M | 61.35M | 63.18M | 62.54M | 57.72M | 60.71M | 61.11M | 59.19M |
| Cash & Equiv | 455.41M | 276.58M | 319.77M | 297.34M | 312.76M | 116.59M | 139.04M | 157.69M | 172.74M | 123.98M | 143.94M | 164.28M |
| Book Value | 387.27M | 211.94M | 246.94M | 218.99M | 248.73M | 55.06M | 71.53M | 88.80M | 108.87M | 53.85M | 74.94M | (49.11M) |
| Return on Equity | -0.12 | -0.20 | -0.11 | -0.15 | -0.11 | -0.39 | -0.26 | -0.29 | -0.19 | -0.45 | 0.64 | N/A |
